UNIVEST FINANCIAL Corp Has $3.22 Million Position in Veeva Systems Inc. $VEEV

UNIVEST FINANCIAL Corp cut its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 38.4% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,806 shares of the technology company’s stock after selling 6,743 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Veeva Systems were worth $3,219,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Veeva Systems by 1.4% in the second quarter. Vanguard Group Inc. now owns 14,971,425 shares of the technology company’s stock valued at $4,311,471,000 after purchasing an additional 210,859 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Veeva Systems by 3.7% in the second quarter. Alliancebernstein L.P. now owns 5,705,648 shares of the technology company’s stock worth $1,643,113,000 after buying an additional 205,997 shares during the last quarter. JPMorgan Chase & Co. raised its position in Veeva Systems by 2.6% during the second quarter. JPMorgan Chase & Co. now owns 3,316,274 shares of the technology company’s stock valued at $955,030,000 after acquiring an additional 85,516 shares in the last quarter. Geode Capital Management LLC raised its position in Veeva Systems by 3.8% during the second quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock valued at $888,108,000 after acquiring an additional 114,003 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Veeva Systems by 111.7% in the second quarter. AQR Capital Management LLC now owns 1,838,046 shares of the technology company’s stock valued at $526,508,000 after acquiring an additional 969,905 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VEEV has been the topic of a number of recent research reports. UBS Group cut their price target on shares of Veeva Systems from $310.00 to $280.00 and set a “neutral” rating on the stock in a report on Friday, November 21st. The Goldman Sachs Group started coverage on shares of Veeva Systems in a research report on Tuesday, January 13th. They set a “sell” rating and a $215.00 target price on the stock. Robert W. Baird raised their price objective on Veeva Systems from $314.00 to $319.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $355.00 price objective on shares of Veeva Systems in a report on Friday, November 21st. Finally, TD Cowen raised Veeva Systems from a “hold” rating to a “buy” rating and increased their target price for the stock from $297.00 to $380.00 in a report on Tuesday, October 7th. Eighteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $308.04.

Veeva Systems Stock Performance

Shares of VEEV opened at $225.11 on Friday. The firm has a market capitalization of $37.00 billion, a price-to-earnings ratio of 43.80, a PEG ratio of 1.62 and a beta of 1.07. Veeva Systems Inc. has a 52 week low of $201.54 and a 52 week high of $310.50. The business’s fifty day moving average price is $234.01 and its two-hundred day moving average price is $267.44.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.09. The business had revenue of $0.81 million for the quarter, compared to analysts’ expectations of $792.37 million. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The firm’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.75 earnings per share. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. As a group, research analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current year.

Veeva Systems announced that its Board of Directors has authorized a share repurchase plan on Monday, January 5th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the technology company to purchase up to 5.5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In related news, insider Thomas D. Schwenger sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total value of $231,430.00. Following the completion of the sale, the insider owned 23,204 shares in the company, valued at approximately $5,370,101.72. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 10.30% of the stock is owned by corporate insiders.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.